VBI Vaccines Inc said on Monday it had entered into an agreement with Canada to develop a potential vaccine for COVID-19 by 2022 through mid-stage trials conducted exclusively in the country.
Canada will contribute around 75% of the U.S.-based company’s development costs and C$55.9 million ($42.2 million) for the project.
VBI Vaccines said last month that together with the National Research Council Canada it was investigating the vaccine candidate, VBI-2900, in preclinical trials.
Get weekly health news
As per the agreement, signed last week, the company’s Ottawa-based unit is obligated to complete the vaccine development in or before the first quarter of 2022.
There are currently no approved vaccines for COVID-19, but around 38 vaccines are being tested in humans around the world.
- Daylight saving time 2026: Here’s when you should set your clocks forward
- Conservative MP searches for ‘antifa’ in federal government, Canadian Armed Forces
- Liberals survive confidence vote as House passes budget implementation bill
- Canadians stranded in Puerto Vallarta after violence disrupts flights home to Edmonton
-
![]()
Jasper mourns best friends killed in crash who played on local hockey team -
![]()
Indian government no longer targeting Canadians, senior official says -
![]()
‘It gives you a reason to get up in the morning’: 95-year-old Ontario skier still on the slopes -
![]()
Canada announces $3.7B plan to build 7,500 new military houses
Comments
Want to discuss? Please read our Commenting Policy first.